Please login to the form below

Not currently logged in
Email:
Password:

rociletinib

This page shows the latest rociletinib news and features for those working in and with pharma, biotech and healthcare.

FDA okays Clovis' Lynparza rival rucaparib

FDA okays Clovis' Lynparza rival rucaparib

The company has been pummelled in recent months after an FDA advisory panel voted against a quick approval of its lung cancer candidate rociletinib, a decision that eventually prompted the company

Latest news

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    An FDA advisory committee all but dashed any hopes that Clovis Oncology had for quick approval of its lung cancer drug rociletinib yesterday. ... Meanwhile Boehringer has a new EGFR inhibitor called BI 1482694 in the pipeline that could now also reach

  • AZ sets price of new lung cancer drug Tagrisso AZ sets price of new lung cancer drug Tagrisso

    The FDA has asked for more data on the drug - called rociletinib - which could potentially hold up the programme by several months. ... The FDA's problems with the dataset for rociletinib hinge on the number of unconfirmed versus confirmed responses to

  • Boehringer takes third-generation NSCLC drug into pivotal trials Boehringer takes third-generation NSCLC drug into pivotal trials

    chemotherapy. Aside from Boehringer, other companies developing third-generation EGFR inhibitors include Clovis Oncology with twice-daily rociletinib (CO-1686) and AZ with once-daily osimertinib/AZD9291, both of which are ... Clinical data on both

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics